Rabies still presents a public health threat causing more than 70,000 human deaths each year. Humans are infected with rabies virus (RV) mostly through bites from rabid domestic or wild animals. Controlling RV infection in domestic and wildlife animals, therefore not only reduces the mortality in these animals but also reduces the risk of human exposure. Pre-exposure vaccinations for people who are constantly at risk further prevent human rabies, as do post-exposure immunization for people who are bitten by rabid or suspected rabied animals. Currently, inactivated RV vaccines are used to immunize domestic pet animals. Purified and inactivated RV vaccines are used for humans in pre- or post-exposure settings. Although inactivated RV vaccines are efficacious, they have problems. First and for most, multiple doses of vaccines over a long period of time are required to stimulate protective immune responses. Furthermore, current tissue culture vaccines are expensive, thus most people in need of vaccination (in developing countries) cannot afford them. Hence, there is a need to develop more efficacious and affordable RV vaccines. In the previous funding period, we made constructs with mutation on both the glycoprotein and the nucleoprotein, resulting in reduced ability to replicate and spread in the nervous system. Here we propose to continue developing avirulent live RV vaccines by constructing mutant RV with enhanced ability to induce innate immune responses (by inserting IFN or chemokine genes into the RV genome), using the state-of-the-art reverse genetics technology. Our proposal is based on our recent findings. Attenuated RV induces strong innate immune responses, particularly IFN and chemokines, thus limiting virus spread within the CNS. The rationale for construction of recombinant RV expressing IFN or chemokines is that such altered RV most likely will have enhanced immunogenicity and can be used as live avirulent vaccines for humans and animals. Furthermore, induction of innate immune responses will not only have a direct anti-viral functions, but also recruit inflammatory cells that can kill infected cells. Such characterists will make these recombinant RV vaccines particularly suitable for post-exposure treatment. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI051560-04A2
Application #
7318256
Study Section
Vaccines Against Microbial Diseases (VMD)
Program Officer
Cassetti, Cristina
Project Start
2002-03-15
Project End
2011-07-31
Budget Start
2007-08-15
Budget End
2008-07-31
Support Year
4
Fiscal Year
2007
Total Cost
$295,000
Indirect Cost
Name
University of Georgia
Department
Pathology
Type
Schools of Veterinary Medicine
DUNS #
004315578
City
Athens
State
GA
Country
United States
Zip Code
30602
Gnanadurai, Clement W; Yang, Yang; Huang, Ying et al. (2015) Differential Host Immune Responses after Infection with Wild-Type or Lab-Attenuated Rabies Viruses in Dogs. PLoS Negl Trop Dis 9:e0004023
Chai, Qingqing; She, Ruiping; Huang, Ying et al. (2015) Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells, production of chemokines and cytokines, and enhancement of blood-brain barrier permeability. J Virol 89:870-6
Yang, Yang; Huang, Ying; Gnanadurai, Clement W et al. (2015) The inability of wild-type rabies virus to activate dendritic cells is dependent on the glycoprotein and correlates with its low level of the de novo-synthesized leader RNA. J Virol 89:2157-69
Gnanadurai, C W; Huang, C T; Kumar, D et al. (2015) Novel Approaches to the Prevention and Treatment of Rabies. Int J Virol Stud Res 3:8-16
Zhou, Ming; Wang, Lei; Zhou, Songqin et al. (2015) Recombinant rabies virus expressing dog GM-CSF is an efficacious oral rabies vaccine for dogs. Oncotarget 6:38504-16
Huang, Ying; Chen, Zhenhai; Huang, Junhua et al. (2015) Parainfluenza virus 5 expressing the G protein of rabies virus protects mice after rabies virus infection. J Virol 89:3427-9
Huang, Chien-Tsun; Li, Zhenguang; Huang, Ying et al. (2014) Enhancement of blood-brain barrier permeability is required for intravenously administered virus neutralizing antibodies to clear an established rabies virus infection from the brain and prevent the development of rabies in mice. Antiviral Res 110:132-41
Chai, Qingqing; He, Wen Q; Zhou, Ming et al. (2014) Enhancement of blood-brain barrier permeability and reduction of tight junction protein expression are modulated by chemokines/cytokines induced by rabies virus infection. J Virol 88:4698-710
Yu, Fulai; Zhang, Guoqing; Zhong, Xiangfu et al. (2014) Comparison of complete genome sequences of dog rabies viruses isolated from China and Mexico reveals key amino acid changes that may be associated with virus replication and virulence. Arch Virol 159:1593-601
Zhang, Guoqing; Wang, Hualei; Mahmood, Fazal et al. (2013) Rabies virus glycoprotein is an important determinant for the induction of innate immune responses and the pathogenic mechanisms. Vet Microbiol 162:601-13

Showing the most recent 10 out of 32 publications